PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.51%
Revenue growth of 5.51% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
-2.33%
Negative gross profit growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-4.92%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-5.57%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-5.25%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-5.25%
Negative EPS growth while Medical - Pharmaceuticals median is 1.72%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-5.25%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 1.41%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.21%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.10%. Seth Klarman would see an advantage if others are still diluting.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.89%
10Y CAGR of 2.89% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
2.89%
5Y CAGR of 2.89% while Medical - Pharmaceuticals is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
-21.33%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
100.00%
OCF/share CAGR of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
100.00%
3Y OCF/share growth of 100.00% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
79.77%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 32.90% over a decade. Joel Greenblatt might see a standout compounder of earnings.
79.77%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 13.92%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-8.48%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
37.97%
Equity/share CAGR of 37.97% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
37.97%
5Y equity/share CAGR of 37.97% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-7.15%
Negative 3Y equity/share growth while Medical - Pharmaceuticals median is 1.66%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.88%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
2.67%
Inventory growth of 2.67% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
2.78%
Asset growth of 2.78% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
3.84%
BV/share growth of 3.84% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-13.52%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
-1.33%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.